Clinical Trial Update: Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lapatinib in combination with trastuzumab or with capecitabine for metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Lapatinib (Lapatinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V. | Conditions: Metastatic Breast Cancer | Phase 2 | Status: WITHDRAWN